Evolent Q2 FY26 net loss narrows to $28.36 million; revenue rises 46.84% to $652.52 million
EVH•Adjusted EBITDA declines
Non-GAAP adjusted EBITDA fell to $28.05 million from $37.55 million a year earlier. Adjusted EBITDA margin slid 4.2 percentage points to 4.3%.
Q2 revenue rises while net loss narrows
Evolent Health posted Q2 2026 revenue of $652.52 million, up 46.85% from a year earlier. Net loss narrowed to $28.36 million.
Loss per share improved to $0.25, and net loss margin tightened by 7.2 percentage points to 4.3%.
Oncology partnership and updated outlook
The company is preparing to launch an Oncology Performance Suite partnership covering about 1.5 million lives. The initiative targets about $300 million in annualized revenue.
Evolent raised its 2026 revenue outlook to $2.6 billion-$2.7 billion and tightened its view to .
